Neuro MSK 18-400

A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.

Eligibility Criteria:

  • Histologic confirmed glioblastoma (WHO grade IV), IDH wildtype confirmed by DNA sequencing
  • MGMT hypermethylation in archival tumor biopsy, determined by any CLIAapproved, DNA-based assay
  • Prior maximal feasible surgical resection of biopsy
  • Prior treatment with radiation and temozolomide chemotherapy
  • Pathologic and/or Radiographic evidence of recurrent disease
  • Circumscribed enhancing tumor ≤ 5.0 cm in largest diameter (T1 post contrast)

Available at: Hartford Hospital